Thrombolex has announced that it will be attending The VEINS (Venous Endovascular INterventional Strategies) conference (Booth T8) and VIVA (Vascular InterVentional Advances) Physicians conference (Booth #502) in Las Vegas, USA from 3–7 October. There will be live demonstrations and meetings with the executive team about the family of Bashir endovascular catheters.
The Bashir endovascular catheter and the Bashir Plus endovascular catheters are intended for the controlled and selective infusion of physician-specified fluids, including thrombolytics, into the peripheral vasculature. They are also now intended for the controlled and selective infusion of physician-specified fluids, including thrombolytics, into the peripheral vasculature, enabling the restoration of blood flow in patients with venous thrombus.
To continue expanding their device’s indication for use, Thrombolex is currently enrolling in its pivotal RESCUE trial for the treatment of patients with acute submassive pulmonary embolism (PE). This trial is using the Bashir endovascular catheter under an Investigational Device Exemption (IDE) from the US Food and Drug Administration (FDA). The goal of RESCUE is to achieve an additional indication for use of the device in the treatment of acute PE.
During the 2021 VIVA conference, the RESCUE trial’s prespecified interim analysis will be presented. This analysis is of the first 60 patients in the trial. The presentation will be on 5 October at 1:30pm local time during the late-breaking clinical trial portion of the meeting. The presentation will be given by Akhilesh Sista, interventional radiologist at NYU Langone (New York, USA).